Company intelligence / Profile preview

MIA Investment

Chicago, Illinois, United States

Ownership: Private
Employees: ~13
Development stage: Other

Overview

Lead candidate ateganosine (THIO) is in Phase 3 pivotal trial (THIO-104) as third-line treatment for advanced non-small cell lung cancer; first patient dosed recently. Also advancing THIO-101 Phase 2 trial and second-generation telomere targeting agents.[1][2][3]

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on MIA Investment.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIA Investment.

Explore the full profile